UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

New hope to prevent ALL relapse after transplant

Blood, 2022-04, Vol.139 (17), p.2580-2581

Bishop, Michael R.

2022

Volltextzugriff (PDF)

The case for CAR T-cell therapy in follicular lymphomas

Blood, 2019-08, Vol.134 (7), p.577-578

Bishop, Michael R.

2019

Volltextzugriff (PDF)

The benefit of CAR T cells in older patients

Blood, 2020-06, Vol.135 (23), p.2020-2021

Bishop, Michael R.

2020

Volltextzugriff (PDF)

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Blood, 2021-06, Vol.137 (24), p.3454-3459

2021

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease

Blood, 2021-11, Vol.138 (Supplement 1), p.3097-3097

2021

Volltextzugriff (PDF)

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7439-7440

2022

Volltextzugriff (PDF)

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.5238-5238

2019

Volltextzugriff (PDF)

Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.1206-1206

2021

Volltextzugriff (PDF)

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Blood, 2022-11, Vol.140 (Supplement 1), p.6594-6595

2022

Volltextzugriff (PDF)

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.366-368

2022

Volltextzugriff (PDF)

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Blood, 2022-11, Vol.140 (Supplement 1), p.10971-10973

2022

Volltextzugriff (PDF)

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood, 2021-11, Vol.138 (Supplement 1), p.2512-2512

2021

Volltextzugriff (PDF)

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Blood, 2017-12, Vol.130, p.3312-3312

2017

Volltextzugriff (PDF)

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Blood, 2019-11, Vol.134 (Supplement_1), p.1956-1956

2019

Volltextzugriff (PDF)

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.48-49

2020

Volltextzugriff (PDF)

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Blood, 2020-11, Vol.136 (Supplement 1), p.39-40

2020

Volltextzugriff (PDF)

Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial

Blood, 2014-08, Vol.124 (6), p.891-898

2014

Volltextzugriff (PDF)

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood, 2021-12, Vol.138 (Supplement 2), p.LBA-6-LBA-6

2021

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Full Collection 2018

ThemaMedical Sciences

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(112)

Sprache

Englisch
(112)
Japanisch
(2)

Erscheinungsjahr

n.n

Kollektion

Zeitschrift / Serie

Blood-The Journal Of Hematology
(1)

Menü

Weitere Dienste

Einstellungen

New hope to prevent ALL relapse after transplant

The case for CAR T-cell therapy in follicular lymphomas

The benefit of CAR T cells in older patients

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission

Aktive Filter

Suchergebnisse filtern